Vascular and Metabolic Effects of Rosuvastatin

Phase 4CompletedNCT01660919

Gachon University Gil Medical Center160 enrolled

Overview

The investigators hypothesize that rosuvastatin does-dependently worsens insulin sensitivity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

160

Conditions

Hypercholesterolemia

Interventions

placeboDRUG

rosuvastatinDRUG

Eligibility

Sex: ALLMin age: 25 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hypercholesterolemia Exclusion Criteria: * overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Locations (1)

Gil Medical Center

Incheon, South Korea

Outcomes

Primary Outcomes

flow-mediated dilation

Time frame: 8 weeks of treatment

Secondary Outcomes

insulin resistance

Time frame: 8 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.